Figure 3
From: Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases
Survival of patients treated with intralesional administered IL-2. Time of diagnosis of stage III respective stage IV disease was taken as the start point for survival curves.
